Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
CONCLUSIONS: Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.PMID:38616529 | DOI:10.1177/10600280241241563 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Haley N Johnson Lalita Prasad-Reddy Source Type: research
Abbreviated Urine Collection Compared With 24-Hour Urine Collection for Measuring Creatinine Clearance in Adult Critically Ill Patients: A Systematic Review
CONCLUSIONS: Abbreviated urine collection may overestimate CrCl compared with 24-hour urine collection. Larger, well-conducted studies are needed to evaluate the accuracy of CrCl measured using different durations of urine collection in critically ill patients.PMID:38619016 | DOI:10.1177/10600280241241820 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Mohamed Omar Saad Adham Mohamed Mohamed Izham Mohamed Ibrahim Source Type: research
Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
CONCLUSIONS: Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.PMID:38616529 | DOI:10.1177/10600280241241563 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Haley N Johnson Lalita Prasad-Reddy Source Type: research
Abbreviated Urine Collection Compared With 24-Hour Urine Collection for Measuring Creatinine Clearance in Adult Critically Ill Patients: A Systematic Review
CONCLUSIONS: Abbreviated urine collection may overestimate CrCl compared with 24-hour urine collection. Larger, well-conducted studies are needed to evaluate the accuracy of CrCl measured using different durations of urine collection in critically ill patients.PMID:38619016 | DOI:10.1177/10600280241241820 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Mohamed Omar Saad Adham Mohamed Mohamed Izham Mohamed Ibrahim Source Type: research
Amiodarone-Induced Psoriasiform Dermatitis
Ann Pharmacother. 2024 Apr 8:10600280241244511. doi: 10.1177/10600280241244511. Online ahead of print.NO ABSTRACTPMID:38590149 | DOI:10.1177/10600280241244511 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Myriam Agrebi Dhouha Sahnoun Najet Ghariani Mohamed Denguezli Chaker Ben Salem Source Type: research
Amiodarone-Induced Psoriasiform Dermatitis
Ann Pharmacother. 2024 Apr 8:10600280241244511. doi: 10.1177/10600280241244511. Online ahead of print.NO ABSTRACTPMID:38590149 | DOI:10.1177/10600280241244511 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Myriam Agrebi Dhouha Sahnoun Najet Ghariani Mohamed Denguezli Chaker Ben Salem Source Type: research
Amiodarone-Induced Psoriasiform Dermatitis
Ann Pharmacother. 2024 Apr 8:10600280241244511. doi: 10.1177/10600280241244511. Online ahead of print.NO ABSTRACTPMID:38590149 | DOI:10.1177/10600280241244511 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Myriam Agrebi Dhouha Sahnoun Najet Ghariani Mohamed Denguezli Chaker Ben Salem Source Type: research
Amiodarone-Induced Psoriasiform Dermatitis
Ann Pharmacother. 2024 Apr 8:10600280241244511. doi: 10.1177/10600280241244511. Online ahead of print.NO ABSTRACTPMID:38590149 | DOI:10.1177/10600280241244511 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Myriam Agrebi Dhouha Sahnoun Najet Ghariani Mohamed Denguezli Chaker Ben Salem Source Type: research
Amiodarone-Induced Psoriasiform Dermatitis
Ann Pharmacother. 2024 Apr 8:10600280241244511. doi: 10.1177/10600280241244511. Online ahead of print.NO ABSTRACTPMID:38590149 | DOI:10.1177/10600280241244511 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 9, 2024 Category: Drugs & Pharmacology Authors: Myriam Agrebi Dhouha Sahnoun Najet Ghariani Mohamed Denguezli Chaker Ben Salem Source Type: research
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support System
CONCLUSION AND RELEVANCE: In patients with heart failure with reduced EF, diltiazem use after nonadherence to a CDSS alert resulted in an increased risk of clinical deterioration. This study highlights the need for improved provider adherence to diltiazem clinical decision support systems.PMID:38571388 | DOI:10.1177/10600280241243071 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 4, 2024 Category: Drugs & Pharmacology Authors: Elizabeth M Foster James C Coons Elena A Puccio Danine Sullinger Rachel Ibrahim Joseph Ibrahim Gavin W Hickey Edward Horn Vincent Mosesso Ryan M Rivosecchi Source Type: research
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support System
CONCLUSION AND RELEVANCE: In patients with heart failure with reduced EF, diltiazem use after nonadherence to a CDSS alert resulted in an increased risk of clinical deterioration. This study highlights the need for improved provider adherence to diltiazem clinical decision support systems.PMID:38571388 | DOI:10.1177/10600280241243071 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 4, 2024 Category: Drugs & Pharmacology Authors: Elizabeth M Foster James C Coons Elena A Puccio Danine Sullinger Rachel Ibrahim Joseph Ibrahim Gavin W Hickey Edward Horn Vincent Mosesso Ryan M Rivosecchi Source Type: research
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support System
CONCLUSION AND RELEVANCE: In patients with heart failure with reduced EF, diltiazem use after nonadherence to a CDSS alert resulted in an increased risk of clinical deterioration. This study highlights the need for improved provider adherence to diltiazem clinical decision support systems.PMID:38571388 | DOI:10.1177/10600280241243071 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 4, 2024 Category: Drugs & Pharmacology Authors: Elizabeth M Foster James C Coons Elena A Puccio Danine Sullinger Rachel Ibrahim Joseph Ibrahim Gavin W Hickey Edward Horn Vincent Mosesso Ryan M Rivosecchi Source Type: research
Clinical Outcomes Associated With Diltiazem Use in Heart Failure With Reduced Ejection Fraction After Implementation of a Clinical Support System
CONCLUSION AND RELEVANCE: In patients with heart failure with reduced EF, diltiazem use after nonadherence to a CDSS alert resulted in an increased risk of clinical deterioration. This study highlights the need for improved provider adherence to diltiazem clinical decision support systems.PMID:38571388 | DOI:10.1177/10600280241243071 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 4, 2024 Category: Drugs & Pharmacology Authors: Elizabeth M Foster James C Coons Elena A Puccio Danine Sullinger Rachel Ibrahim Joseph Ibrahim Gavin W Hickey Edward Horn Vincent Mosesso Ryan M Rivosecchi Source Type: research
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Alexa J Luboff David L DeRemer Source Type: research
Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 3, 2024 Category: Drugs & Pharmacology Authors: Alexa J Luboff David L DeRemer Source Type: research
